TY - JOUR
T1 - Enhanced vitamin K (Menaquinone-7) production by Bacillus subtilis natto in biofilm reactors by optimization of glucose-based medium
AU - Mahdinia, Ehsan
AU - Demirci, Ali
AU - Berenjian, Aydin
N1 - Funding Information:
This work was supported by the USDA National Institute of Food and Agriculture Federal Appropriations under Project PEN04561 and Accession number 1002249. The authors thank the Statistical Consulting Center at The Pennsylvania State University for their support in providing useful consultation for data processing.
Publisher Copyright:
© 2018 Bentham Science Publishers.
PY - 2019
Y1 - 2019
N2 - Background: Benefits of vitamin K have been reported by many studies recently, due to its ability to reduce the risk of cardiovascular diseases and its potential benefits against osteoporosis. Specifically, menaquinone-7 (MK-7), being the most potent form of vitamin K, has definitely received most of the attention. Currently, solid or static liquid fermentation strategies are utilized for industrial production of MK-7 by Bacillus strains. However, these strategies face fundamental operational and scale-up issues as well as intense pellicle and biofilm formations which is problematic in static liquid fermentation, due to heat and mass transfer inefficiencies they create. Objective: The purpose of this study was to demonstrate that biofilm reactors will overcome the issues associated with suspended cell reactors when using Bacillus strains to produce MK-7. The expectation is that the use of biofilm reactors will result in a significant increase in the production of MK-7. Method: Vitamin K production by Bacillus subtilis natto when grown in a biofilm reactor was evaluated at various concentrations of the three major nutrients, glucose, yeast extract and casein. The data was analyzed using response surface methodology (RSM). Results: The maximum concentration of MK-7 in the biofilm reactors was 20.5±0.5 mg/L, which was a 344 % increase when compared to the amount produced in suspended-cell reactors containing the same optimum media composition. Conclusion: These results demonstrate the potential of utilizing biofilm reactors for MK-7 production on an industrial scale.
AB - Background: Benefits of vitamin K have been reported by many studies recently, due to its ability to reduce the risk of cardiovascular diseases and its potential benefits against osteoporosis. Specifically, menaquinone-7 (MK-7), being the most potent form of vitamin K, has definitely received most of the attention. Currently, solid or static liquid fermentation strategies are utilized for industrial production of MK-7 by Bacillus strains. However, these strategies face fundamental operational and scale-up issues as well as intense pellicle and biofilm formations which is problematic in static liquid fermentation, due to heat and mass transfer inefficiencies they create. Objective: The purpose of this study was to demonstrate that biofilm reactors will overcome the issues associated with suspended cell reactors when using Bacillus strains to produce MK-7. The expectation is that the use of biofilm reactors will result in a significant increase in the production of MK-7. Method: Vitamin K production by Bacillus subtilis natto when grown in a biofilm reactor was evaluated at various concentrations of the three major nutrients, glucose, yeast extract and casein. The data was analyzed using response surface methodology (RSM). Results: The maximum concentration of MK-7 in the biofilm reactors was 20.5±0.5 mg/L, which was a 344 % increase when compared to the amount produced in suspended-cell reactors containing the same optimum media composition. Conclusion: These results demonstrate the potential of utilizing biofilm reactors for MK-7 production on an industrial scale.
UR - http://www.scopus.com/inward/record.url?scp=85057496980&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057496980&partnerID=8YFLogxK
U2 - 10.2174/1389201020666181126120401
DO - 10.2174/1389201020666181126120401
M3 - Article
C2 - 30474527
AN - SCOPUS:85057496980
SN - 1389-2010
VL - 19
SP - 917
EP - 924
JO - Current Pharmaceutical Biotechnology
JF - Current Pharmaceutical Biotechnology
IS - 11
ER -